This is a news story, published by CNBC, that relates primarily to Novo Nordisk news.
For more Novo Nordisk news, you can click here:
more Novo Nordisk newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Novo Nordisk. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest NovoCare news, online pharmacy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weight loss drug WegovyCNBC
•Health
Health
72% Informative
Novo Nordisk will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy.
The pharmacy, called NovoCare , will allow patients to pay $ 499 in cash per month for the weekly drug.
The cash-pay offering is available to millions of patients without insurance coverage for the blockbuster injection.
VR Score
65
Informative language
61
Neutral language
41
Article tone
semi-formal
Language
English
Language complexity
47
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links
